...
首页> 外文期刊>Orphanet journal of rare diseases >Cardiomyopathy, familial dilated
【24h】

Cardiomyopathy, familial dilated

机译:心肌病,家族性扩张

获取原文

摘要

Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilatation and impaired systolic function. Patients with DCM suffer from heart failure, arrhythmia, and are at risk of premature death. DCM has a prevalence of one case out of 2500 individuals with an incidence of 7/100,000/year (but may be under diagnosed). In many cases the disease is inherited and is termed familial DCM (FDC). FDC may account for 20–48% of DCM. FDC is principally caused by genetic mutations in FDC genes that encode for cytoskeletal and sarcomeric proteins in the cardiac myocyte. Family history analysis is an important tool for identifying families affected by FDC. Standard criteria for evaluating FDC families have been published and the use of such criteria is increasing. Clinical genetic testing has been developed for some FDC genes and will be increasingly utilized for evaluating FDC families. Through the use of family screening by pedigree analysis and/or genetic testing, it is possible to identify patients at earlier, or even presymptomatic stages of their disease. This presents an opportunity to invoke lifestyle changes and to provide pharmacological therapy earlier in the course of disease. Genetic counseling is used to identify additional asymptomatic family members who are at risk of developing symptoms, allowing for regular screening of these individuals. The management of FDC focuses on limiting the progression of heart failure and controlling arrhythmia, and is based on currently accepted treatment guidelines for DCM. It includes general measures (salt and fluid restriction, treatment of hypertension, limitation of alcohol intake, control of body weight, moderate exercise) and pharmacotherapy. Cardiac resynchronization, implantable cardioverter defibrillators and left ventricular assist devices have progressively expanding usage. Patients with severe heart failure, severe reduction of the functional capacity and depressed left ventricular ejection fraction have a low survival rate and may require heart transplant.
机译:扩张型心肌病(DCM)是一种以心室扩张和收缩功能受损为特征的心肌疾病。 DCM患者患有心力衰竭,心律不齐,并有过早死亡的风险。 DCM在2500名患者中有1例患病率,每年的发病率为7 / 100,000(但可能未得到诊断)。在许多情况下,该疾病是遗传性的,被称为家族性DCM(FDC)。 FDC可能占DCM的20–48%。 FDC主要是由编码心肌细胞中细胞骨架和肌节蛋白的FDC基因的遗传突变引起的。家族史分析是识别受FDC影响的家庭的重要工具。评估FDC家庭的标准标准已经发布,并且这种标准的使用正在增加。已经为某些FDC基因开发了临床遗传测试,并将越来越多地用于评估FDC家族。通过使用家谱分析和/或基因检测进行家庭筛查,有可能识别出处于疾病早期或更症状前期的患者。这为在疾病过程中提早改变生活方式并提供药理学治疗提供了机会。遗传咨询可用于识别其他可能出现症状的无症状家庭成员,从而可以定期筛查这些个体。 FDC的管理着重于限制心力衰竭的进展和控制心律不齐,并基于目前公认的DCM治疗指南。它包括一般措施(盐和液体限制,高血压的治疗,酒精摄入的限制,体重控制,适度运动)和药物疗法。心脏再同步,植入式心脏复律除颤器和左心室辅助设备的使用范围正在逐步扩大。患有严重心力衰竭,功能能力严重下降和左心室射血分数降低的患者生存率较低,可能需要进行心脏移植。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号